AstraZeneca: EU approves new dosing for lung cancer drug

(CercleFinance.com) - European drug regulators have approved AstraZeneca's Imfinzi in a less-frequent dosing option for unresectable non-small cell lung cancer.


The green light from the European Commission follows an accelerated assessment by the European Medicines Agency, which resulted in a recommendation approval in December 2020.

The new, less-frequent dosing option meets an urgent need during the pandemic, as lung cancer patients are especially vulnerable to complications from Covid-19.

The approval also applies to the UK, despite Brexit, AstraZeneca said.

Copyright (c) 2021 CercleFinance.com. All rights reserved.